« Return to News | Study Conduct

Inclinix and JSW Life Sciences form strategic partnership

Thursday, February 23, 2012 06:16 AM

Inclinix, which specializes in customized phase I-IV clinical enrollment solutions, has selected CRO JSW Life Sciences as its European partner to support enrollment of its clinical trials throughout Europe.

The strategic partnership places Inclinix offices in Graz, Austria, and expands Inclinix by more than 100 enrollment professionals in Eastern and Western Europe.

"As Inclinix has experienced significant growth over the past year, it has been important for us to identify a European partner that shares our philosophy and performance enrollment model," said J. Tobin Geatz, Inclinix president and CEO.

The Inclinix Clinical Enrollment Manager (CEM) programs offer a unique approach to global clinical trial enrollment. CEMs provide in-field enrollment support to investigative sites, focusing on identifying qualified study candidates not only from within the sites' practices, but also from the surrounding medical and patient communities.

"We are excited to combine our clinical expertise and native-language teams with Inclinix's enrollment experience. We look forward to many successful enrollment campaigns through this partnership,” said Dr. Manfred Windisch, CEO of JSW Life Sciences.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.